MicroRNA 193b (miR-193b)

MicroRNA 193b (miR-193b) is a non-coding small RNA (approximately 20-24 nucleotides) that regulates gene expression at the post-transcriptional level by binding to the 3' untranslated regions (3′UTRs) of target mRNAs, leading to mRNA degradation or translational repression[4][7]. It is transcribed as part of a capped and polyadenylated primary transcript, processed through Drosha and Dicer enzymes, and incorporated into the RNA-induced silencing complex (RISC)[4]. MiR-193b participates in various cellular processes such as cell cycle regulation, apoptosis, proliferation, migration, and invasion, and is functionally implicated in multiple cancers, including acting as either a tumor suppressor (e.g., in leukemia and colon cancer) or an oncogene (e.g., in glioma and head and neck cancer), depending on the cellular context[2][3][5][6][7]. Disease-linked regulatory targets include DDAH1, NF1, RAB22A, SMAD3, cyclin D1, ETS1, and MCL-1[1][3][5]. Its expression pattern and functional consequences underpin its value as a diagnostic and prognostic biomarker in various malignancies and its potential as a therapeutic target, although context-specific activity and broad transcriptome interaction present therapeutic challenges[2][5][6][7].

Other names

hsa-mir-193bMIRN193Bmir-193bMIR193Bhsa-miR-193bmiR-193b-3p

Modulation of downstream gene expression via mRNA binding causing mRNA degradation or translation inhibition[1][4]; Inhibition of pro-proliferative signaling pathways (e.g., RAS/MAPK, STAT5) in some settings[5][6][7]; Targeting of specific genes such as DDAH1, NF1, RAB22A, SMAD3, cyclin D1, ETS1, uPA, HSP40, MCL-1[1][3][5]